<DOC>
	<DOCNO>NCT02786186</DOCNO>
	<brief_summary>The main purpose current study provide real - world evidence regard safety effectiveness secukinumab management patient moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>A Registry Patients With Moderate Severe Plaque Psoriasis</brief_title>
	<detailed_description>PURE multi-national , prospective , observational cohort study patient moderate severe chronic plaque psoriasis aim assess real-world safety effectiveness secukinumab indicate therapy . The study enroll patient , prior independent study enrollment , treat physician decide treat secukinumab , one indicated therapy regimens approved management moderate severe chronic plaque psoriasis . Two study cohort define patient treat secukinumab ( Cohort 1 ) , patient treat indicated therapy ( systemic , phototherapy , biologic therapy ; Cohort 2 ) . Each investigator recruit approximately number patient treatment arm . 2,500 patient ( 1,250 patient cohort ) follow period 5 year Baseline assessment ( Visit 1 ) .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Patients able give write informed consent 2 . Patients least 18 year age time inform consent signature 3 . Confirmed diagnosis chronic moderate severe chronic plaquetype psoriasis diagnose specialist presence moderate severe psoriasis symptom accord physician 's clinical judgment time recruitment . 4 . Patients initiate treatment psoriasis per regional policy . This include secukinumab , biologics , systemic treatment , phototherapy . Decision treat abovementioned treatment must reach prior independently recruitment study . 5 . Treatments prescribed accordance product monograph regional regulatory reimbursement policy 6 . Patients able understand communicate investigator comply requirement study . 1 . Unwillingness inability comply study requirement 2 . Participation clinical trial investigational drug , concurrently within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Plaque Psoriasis</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Cosentyx</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>Moderate severe plaque psoriasis</keyword>
	<keyword>PURE registry</keyword>
	<keyword>Registry</keyword>
</DOC>